Coldstream Capital Management Inc. Buys 100 Shares of Cencora, Inc. (NYSE:COR)

Coldstream Capital Management Inc. grew its stake in shares of Cencora, Inc. (NYSE:COR) by 3.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 3,399 shares of the company’s stock after acquiring an additional 100 shares during the quarter. Coldstream Capital Management Inc.’s holdings in Cencora were worth $764,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of COR. Hancock Whitney Corp lifted its position in shares of Cencora by 0.9% during the 4th quarter. Hancock Whitney Corp now owns 75,035 shares of the company’s stock worth $16,859,000 after buying an additional 671 shares during the last quarter. Voya Investment Management LLC lifted its position in shares of Cencora by 5.8% during the 4th quarter. Voya Investment Management LLC now owns 310,646 shares of the company’s stock worth $69,796,000 after buying an additional 17,064 shares during the last quarter. Coppell Advisory Solutions LLC lifted its position in shares of Cencora by 97.9% during the 4th quarter. Coppell Advisory Solutions LLC now owns 384 shares of the company’s stock worth $86,000 after buying an additional 190 shares during the last quarter. CSM Advisors LLC lifted its position in shares of Cencora by 1.0% during the 4th quarter. CSM Advisors LLC now owns 26,617 shares of the company’s stock worth $5,982,000 after buying an additional 256 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new stake in shares of Cencora during the 4th quarter worth $4,914,000. 97.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Cencora

In other Cencora news, CEO Robert P. Mauch sold 4,969 shares of the firm’s stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $289.33, for a total value of $1,437,680.77. Following the completion of the sale, the chief executive officer now owns 47,582 shares of the company’s stock, valued at approximately $13,766,900.06. This trade represents a 9.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Lazarus Krikorian sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the completion of the sale, the chief accounting officer now directly owns 20,154 shares of the company’s stock, valued at $5,241,249.24. This trade represents a 9.03 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,223 shares of company stock valued at $13,580,967. Company insiders own 10.80% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on COR shares. Evercore ISI upped their price objective on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Wells Fargo & Company increased their target price on Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a research report on Friday, March 14th. JPMorgan Chase & Co. increased their target price on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Bank of America increased their target price on Cencora from $270.00 to $285.00 and gave the company a “neutral” rating in a research report on Friday, April 11th. Finally, StockNews.com upgraded Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $284.55.

Cencora Trading Up 0.6 %

NYSE COR opened at $287.75 on Tuesday. The business has a 50 day simple moving average of $268.94 and a 200 day simple moving average of $250.00. Cencora, Inc. has a one year low of $214.77 and a one year high of $296.65. The stock has a market capitalization of $55.80 billion, a P/E ratio of 40.93, a P/E/G ratio of 1.31 and a beta of 0.55. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR) last released its earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.76%. Cencora’s dividend payout ratio (DPR) is presently 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.